5414x Site

: 58.2%, slightly down from 58.8% in H1 2024 due to one-off inventory charges and currency headwinds, despite an underlying improvement of 525 basis points. Segment Growth :

: £72.1 million, a 22.1% increase compared to H1 2024 (£59.0 million). Gross Profit : £61.4 million, up 24% year-on-year.

: Continued advancement in national programs like NIHR Bioresource. Strategic and Operational Developments

: £12.9 million (+27.4%), supported by synthetic biology.

: £13.0 million (+52.9%), driven by AMR and EMEAI growth.

: Established a strategic collaboration with Cepheid (a Danaher subsidiary) to develop automated infectious disease sequencing solutions. Leadership Update

Co-founder and CEO announced he will step down from his role and the board by the end of 2026.